NMR-based metabolomics: Translational application and treatment of cancer

N. J. Serkova, J. L. Spratlin, S. G. Eckhardt

Research output: Contribution to journalReview article

84 Citations (Scopus)

Abstract

Cancer cells possess a highly unique metabolic phenotype which is characterized by high glucose uptake, increased glycolytic activity, decreased mitochondrial activity, low bioenergetic expenditure and increased phospholipid turnover. In addition to these general metabolic markers of malignancy, tissue-specific biochemistry has identified specific endogenous metabolites found in particular tumors types. These include N-acetyl aspartate in neuroblastoma, myo-inositol in gliomas and citrate in prostate cancer. Metabolic profiles can be readily assessed to monitor responsiveness and the development of resistance to novel targeted drugs, for example, where a cytostatic effect rather than cytotoxicity occurs. Using modern analytical technologies in combination with statistical approaches, a methodology termed 'metabolomics' has been developed. Metabolomics has been used to generate a global metabolic profile on patient samples, which can then be used to determine treatment response. This review describes existing NMR-based approaches for global metabolic profiling in tissue biopsies and body fluids and the use of non-invasive radiological techniques to assess metabolic biomarkers. In addition, studies on metabolic responses to novel targeted drugs, including tyrosine kinase inhibitors and metabolic modulators, are evaluated.

Original languageEnglish (US)
Pages (from-to)572-585
Number of pages14
JournalCurrent Opinion in Molecular Therapeutics
Volume9
Issue number6
StatePublished - Dec 1 2007

Fingerprint

Metabolomics
Metabolome
Neoplasms
Cytostatic Agents
Body Fluids
Inositol
Health Expenditures
Neuroblastoma
Citric Acid
Glioma
Pharmaceutical Preparations
Biochemistry
Protein-Tyrosine Kinases
Energy Metabolism
Phospholipids
Prostatic Neoplasms
Therapeutics
Biomarkers
Technology
Phenotype

Keywords

  • Cancer biomarkers
  • Cancer treatment
  • Choline metabolism
  • Quantitative metabolomics
  • Signal transduction inhibitor
  • Warburg effect

ASJC Scopus subject areas

  • Molecular Medicine
  • Molecular Biology
  • Genetics
  • Pharmacology
  • Drug Discovery
  • Genetics(clinical)

Cite this

NMR-based metabolomics : Translational application and treatment of cancer. / Serkova, N. J.; Spratlin, J. L.; Eckhardt, S. G.

In: Current Opinion in Molecular Therapeutics, Vol. 9, No. 6, 01.12.2007, p. 572-585.

Research output: Contribution to journalReview article

@article{fcd5f4a6fd8d45d9ab1efb4154a8cb9d,
title = "NMR-based metabolomics: Translational application and treatment of cancer",
abstract = "Cancer cells possess a highly unique metabolic phenotype which is characterized by high glucose uptake, increased glycolytic activity, decreased mitochondrial activity, low bioenergetic expenditure and increased phospholipid turnover. In addition to these general metabolic markers of malignancy, tissue-specific biochemistry has identified specific endogenous metabolites found in particular tumors types. These include N-acetyl aspartate in neuroblastoma, myo-inositol in gliomas and citrate in prostate cancer. Metabolic profiles can be readily assessed to monitor responsiveness and the development of resistance to novel targeted drugs, for example, where a cytostatic effect rather than cytotoxicity occurs. Using modern analytical technologies in combination with statistical approaches, a methodology termed 'metabolomics' has been developed. Metabolomics has been used to generate a global metabolic profile on patient samples, which can then be used to determine treatment response. This review describes existing NMR-based approaches for global metabolic profiling in tissue biopsies and body fluids and the use of non-invasive radiological techniques to assess metabolic biomarkers. In addition, studies on metabolic responses to novel targeted drugs, including tyrosine kinase inhibitors and metabolic modulators, are evaluated.",
keywords = "Cancer biomarkers, Cancer treatment, Choline metabolism, Quantitative metabolomics, Signal transduction inhibitor, Warburg effect",
author = "Serkova, {N. J.} and Spratlin, {J. L.} and Eckhardt, {S. G.}",
year = "2007",
month = "12",
day = "1",
language = "English (US)",
volume = "9",
pages = "572--585",
journal = "Current Opinion in Molecular Therapeutics",
issn = "1464-8431",
publisher = "Current Drugs Ltd.",
number = "6",

}

TY - JOUR

T1 - NMR-based metabolomics

T2 - Translational application and treatment of cancer

AU - Serkova, N. J.

AU - Spratlin, J. L.

AU - Eckhardt, S. G.

PY - 2007/12/1

Y1 - 2007/12/1

N2 - Cancer cells possess a highly unique metabolic phenotype which is characterized by high glucose uptake, increased glycolytic activity, decreased mitochondrial activity, low bioenergetic expenditure and increased phospholipid turnover. In addition to these general metabolic markers of malignancy, tissue-specific biochemistry has identified specific endogenous metabolites found in particular tumors types. These include N-acetyl aspartate in neuroblastoma, myo-inositol in gliomas and citrate in prostate cancer. Metabolic profiles can be readily assessed to monitor responsiveness and the development of resistance to novel targeted drugs, for example, where a cytostatic effect rather than cytotoxicity occurs. Using modern analytical technologies in combination with statistical approaches, a methodology termed 'metabolomics' has been developed. Metabolomics has been used to generate a global metabolic profile on patient samples, which can then be used to determine treatment response. This review describes existing NMR-based approaches for global metabolic profiling in tissue biopsies and body fluids and the use of non-invasive radiological techniques to assess metabolic biomarkers. In addition, studies on metabolic responses to novel targeted drugs, including tyrosine kinase inhibitors and metabolic modulators, are evaluated.

AB - Cancer cells possess a highly unique metabolic phenotype which is characterized by high glucose uptake, increased glycolytic activity, decreased mitochondrial activity, low bioenergetic expenditure and increased phospholipid turnover. In addition to these general metabolic markers of malignancy, tissue-specific biochemistry has identified specific endogenous metabolites found in particular tumors types. These include N-acetyl aspartate in neuroblastoma, myo-inositol in gliomas and citrate in prostate cancer. Metabolic profiles can be readily assessed to monitor responsiveness and the development of resistance to novel targeted drugs, for example, where a cytostatic effect rather than cytotoxicity occurs. Using modern analytical technologies in combination with statistical approaches, a methodology termed 'metabolomics' has been developed. Metabolomics has been used to generate a global metabolic profile on patient samples, which can then be used to determine treatment response. This review describes existing NMR-based approaches for global metabolic profiling in tissue biopsies and body fluids and the use of non-invasive radiological techniques to assess metabolic biomarkers. In addition, studies on metabolic responses to novel targeted drugs, including tyrosine kinase inhibitors and metabolic modulators, are evaluated.

KW - Cancer biomarkers

KW - Cancer treatment

KW - Choline metabolism

KW - Quantitative metabolomics

KW - Signal transduction inhibitor

KW - Warburg effect

UR - http://www.scopus.com/inward/record.url?scp=36549000754&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=36549000754&partnerID=8YFLogxK

M3 - Review article

C2 - 18041668

AN - SCOPUS:36549000754

VL - 9

SP - 572

EP - 585

JO - Current Opinion in Molecular Therapeutics

JF - Current Opinion in Molecular Therapeutics

SN - 1464-8431

IS - 6

ER -